Stock NTP ABLIVA AB
Add to a list
To use this feature you must be a member
Log inSign up

Abliva AB Share Price Deutsche Boerse AG

Equities

NTP

SE0002575340

Biotechnology & Medical Research

Delayed Deutsche Boerse AG
Other stock markets
 08:46:25 17/07/2024 BST 		5-day change 1st Jan Change
0.0128 EUR +0.79% Intraday chart for Abliva AB +70.67% +4.07%
05-30 Abliva Concludes Dosing in Mid-stage Study of Mitochondrial Disease Drug MT
05-30 Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease CI

Financials

Sales 2024 * - Sales 2025 * - Capitalization 293M 27.92M 25.51M 2.14B
Net income 2024 * -128M -12.18M -11.13M -934M Net income 2025 * -146M -13.89M -12.69M -1.06B EV / Sales 2024 * -
Net cash position 2024 * 22M 2.09M 1.91M 160M Net cash position 2025 * 82M 7.8M 7.13M 598M EV / Sales 2025 * -
P/E ratio 2024 *
-2.18 x
P/E ratio 2025 *
-1.81 x
Employees 6
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.06%
More Fundamentals * Assessed data

Chart Abliva AB

Dynamic Chart

Latest news about Abliva AB

Abliva Concludes Dosing in Mid-stage Study of Mitochondrial Disease Drug MT
Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease CI
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : Abliva AB - Special Call
Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study CI
EU Commission Grants Orphan Drug Designation to Abliva’s Mitochondrial Disease Drug Candidate; Stock Jumps MT
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Abliva AB and Owl Therapeutics Enter into Licensing and Collaboration Agreement for NeuroSTAT in Traumatic Brain Injury CI
Abliva AB Achieves Important Milestone in the Ongoing FALCON Study CI
Abliva Rises 28% on US FDA Fast Track Designation for Mitochondrial Disease Drug Candidate MT
Abliva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Abliva AB Announces First Patient Dosed in the Falcon Study CI
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Abliva AB Announces Resignation of Edwin Moses as Director CI
More news

Latest transcript on Abliva AB

Logo Abliva AB
Abliva AB - Special Call
More transcripts

Press releases Abliva AB

Amended number of shares and votes in Abliva AB (publ) AQ
Abliva Announces Completion of 24 Weeks of Dosing in Wave 1 of the FALCON Study of KL1333 in Primary Mitochondrial Disease AQ
Ablivas CEO to BioStock: "We remain on track for the interim analysis early in Q3" AQ
Resolutions from Annual General Meeting in Abliva AB (publ) on May 23, 2024 AQ
Abliva : Interim Report January - March 2024 PU
More press releases

Quotes and Performance

1 day+0.79%
1 week+70.67%
Current month+146.15%
1 month+60.00%
3 months+64.10%
6 months+10.34%
Current year+4.07%
More quotes

Highs and lows

1 week
0.01
Extreme 0.0088
0.01
1 month
0.00
Extreme 0.0001
0.01
Current year
0.00
Extreme 0.0001
0.03
1 year
0.00
Extreme 0.0001
0.03
3 years
0.00
Extreme 0.0001
0.06
5 years
0.00
Extreme 0.0001
0.22
10 years
0.00
Extreme 0.0001
8.75
More quotes

Managers and Directors - Abliva AB

Managers TitleAgeSince
Ellen Donnelly CEO
 Chief Executive Officer 50 02/02/21
Eskil Elmér FOU
 Founder 54 31/01/00
Catharina Jz Johansson DFI
 Director of Finance/CFO 57 30/11/13
Members of the board TitleAgeSince
David Laskow-Pooley CHM
 Chairman 70 27/04/16
David Bejker BRD
 Director/Board Member 49 26/04/17
Eskil Elmér FOU
 Founder 54 31/01/00
More insiders

Quotes

Date Price Change
17/07/24 0.0128 +0.79%
16/07/24 0.0127 -5.22%
15/07/24 0.0134 -8.22%
12/07/24 0.0146 +3.55%
11/07/24 0.0141 +88.00%

Delayed Quote Deutsche Boerse AG, July 17, 2024 at 08:46 am

More quotes

Company Profile

Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.
Sector
Biotechnology & Medical Research
Calendar
14/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.17% 126B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+24.67% 118B
ARGENX SE Stock argenx SE
+23.67% 27.87B
BIONTECH SE Stock BioNTech SE
-17.74% 20.95B
GENMAB A/S Stock Genmab A/S
-15.75% 16.92B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.21% 16.18B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.91% 14.84B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.10% 14.79B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+54.50% 14.08B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ABLI Stock
  4. NTP Stock